MAP2K7 and pancreatic neoplasm: Although pancreatic cancer has not yet benefited from immunotherapy, MEK inhibitors have been proven to increase T cell infiltration in the tumor microenvironment and present significant synergies with immunotherapy such as programmed death-receptor 1 (PD-1) and programmed cell death-ligand 1 (PD-L1), compared with MEK inhibitors alone 77.